Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Barclays
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $244.96 -0.36%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $235.00 (from $233.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
